Eli Lilly (LLY) Capital Expenditures (2009 - 2026)

Eli Lilly has reported Capital Expenditures for 18 years, with the latest figure at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 54.04% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $8.7 billion (up 55.1% YoY), and the FY2025 full-year result was $7.8 billion, up 55.02% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.3 billion, down from $2.5 billion in the prior quarter.
• The five-year high for Capital Expenditures was $2.5 billion in Q4 2025, with the low at $365.4 million in Q1 2022.
• Historically, Capital Expenditures has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
• Annual changes were most pronounced in 2022 — Capital Expenditures slipped 2.7% — and 2023, when it soared 113.9%.
• Eli Lilly's Capital Expenditures stood at $500.7 million in 2022, then soared by 113.9% to $1.1 billion in 2023, then surged by 39.7% to $1.5 billion in 2024, then jumped by 70.21% to $2.5 billion in 2025, then decreased by 8.67% to $2.3 billion in 2026.
• The last three Capital Expenditures figures came in at $2.3 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.